There are four different kinds of VEGF (receptor) inhibitors available for cancer therapy: (1) bevacizumab, a humanized mAb, directs against VEGFA in the circulation [53]; (2) ramucirumab is a mAb that acts directly on cellular VEGF receptors [54]; (3) aflibercept, a soluble decoy receptor, blocks tumor angiogenesis by binding to VEGF; (4) sunitinib, sorafenib, vandetanib, pazopanib, regorafenib, axitinib, cabozantinib, fotivda and so on are small-molecule TKIs that suppress intracellular and downstream signalings [55]. The gene discussed is VEGFA; the disease is neoplasm.